Tetra Bio-Pharma announced the signing of a first binding term sheet for the marketing and distribution of its product PPP001 in Israel with Kamada, a pharmaceutical company.

Tetra Bio-Pharma (TSXV:TBP; OTCQB:TBPMF) announced the signing of a first binding term sheet for the marketing and distribution of its product PPP001 in Israel with Kamada, a pharmaceutical company.

As quoted in the press release:

The signing of a Definitive Distribution Agreement is expected to follow shortly. PPP001 is being developed to be the first smokable cannabis product for advanced cancer pain available under prescription.
This first international market commercialization agreement represents a significant milestone and a validation of Tetra Bio-Pharma’s business model with a leading Israel-based pharmaceutical company. Israel, like Canada, is considered one of the world leaders in the production and development of cannabinoid-based products. Kamada is a company with two FDA-approved products and an Israeli-based distribution segment that has demonstrated continued growth. Tetra Bio-Pharma intends to work closely with Kamada as PPP001 advances towards regulatory approval and commercial launch in Israel.

Click here to read the full press release.

Source: www.marketwired.com

a pharmaceutical company approval canada cancer cannabinoid distribution agreement fda fda-approved international market pain Cannabis Investing